Inhibitors of the ERK mitogen-activated protein kinase cascade for targeting RAS mutant cancers.

Abstract excerpt

Although recent success in identifying direct inhibitors of mutant Ras has begun to challenge the perception that Ras is "undruggable," the successful transition of these hits to the clinic remains uncertain. Therefore, current efforts to develop anti-Ras inhibitors are focused on indirect approaches, with inhibitors of the downstream effectors of Ras signaling having attracted the greatest current interest. Of...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Enzyme Inhibitors
• Share to Extracellular Signal-Regulated MAP Kinases